Dr. Amer Kechli Provides Perspective to Medscape on Study Presented at ERS on Children With Moderate-to-Severe Asthma With Type 2 Inflammation Treated With Dupilumab

Amer Kechli, MD, Professor of Clinical Pediatrics at the Lewis Katz School of Medicine at Temple University, provided perspective to Medscape on findings presented at ERS related to children with moderate-to-severe asthma with type 2 inflammation treated with dupilumab. The post hoc analysis found those children treated with dupilumab were at least twice as likely to achieve clinical remission after one year compared to those treated with placebo. Kechli, who was not involved in the study, emphasized the importance of shifting the “treatment goal paradigm” in pediatric asthma toward clinical remission rather than reducing the frequency of symptoms and exacerbations.